GlaxoSmithKline PLC Looks to Continue to Trade Above its Annual-High Share Price Today

August 18, 2021 10:55:52

GlaxoSmithKline PLC (NYSE:GSK) traded at a new 52-week high today of $42.68. This new high was reached on below average trading volume as 1.4 million shares traded hands, while the average 30-day volume is approximately 3.8 million shares.

There is potential upside of 23.4% for shares of GlaxoSmithKline PLC based on a current price of $42.49 and an average consensus analyst price target of $52.42.

In the past 52 weeks, GlaxoSmithKline PLC share prices are bracketed by a low of $33.26 and a high of $42.68 and is now at $42.49, 28% above that low price.

In the pharmaceutical industry, GlaxoSmithKline ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, oncology, and antiviral, as well as vaccines and consumer healthcare products. Glaxo uses joint ventures to gain additional scale in certain markets like HIV and consumer products.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit

About InvestorBrandNetwork (IBN)
InvestorBrandNetwork (IBN) consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: